This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Clinical trials play a crucial role in advancing medical breakthroughs, but effective management is essential to unlock their full potential. Pharmaceuticalcompanies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources.
Insights for Thought Leading Stakeholder Engagement to Decrease Medication Non-Adherence Pharmaceuticalcompanies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinicalresearch, drug development, and medical education.
The recent draft by the FDA introduces additional guidelines for Diversity Action Plans aimed at improving diversity in clinicalresearch. Hence, pharmaceuticalcompanies need to start making preparations to ensure compliance with the new requirements.
AOP Orphan – AOP Orphan Pharmaceuticals took over the Viennese pharmaceuticalcompany Amomed and the Luxembourgish health-tech company SciPharm. AOP anticipates new opportunities in Austria as a hub for research and business. All jobs have been maintained and the workforce has grown from about 220 to 350.
However, my goal was all the time to work with drug development in the pharma industry, so I moved on and started that journey in 1992 when I took on a role as ClinicalResearch Manager at AstraHässle, a mid-size Swedish pharmacompany.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content